ISMRM 25th Annual Meeting & Exhibition • 22-27 April 2017 • Honolulu, HI, USA
|Sunrise Educational Session: Assessing Response to Immunotherapy|
ORGANIZERS: Linda Moy, M.D. & Valeria Panebianco, M.D.
Tuesday, 25 April 2017
Skill Level: Intermediate to Advanced
Slack Channel: #e_cancer_mol_mrs
Session Number: STu07
Cancer immunotherapy attempts to stimulate the immune system to reject and destroy tumors. This novel treatment uses certain components of a person’s immune system to fight malignancy either as a single chemotherapy agent or in combination with existing chemotherapy regimens. Immunotherapy includes monoclonal antibodies targeted to a specific receptor in cancer cells or cancer vaccines. There is an unmet need to develop targeted imaging agents to assess response to immunotherapy.
There is a broad range of attendees that may benefit from this course. Cancer imaging specialists that are interested in immunotherapy. MR physicist who desire to learn more about this novel treatment. Attendees who are interested in targeted imaging agents.
Upon completion of this course, participants should be able to:
-Review how the immune system may fail to recognize cancer cells as foreign;
-Explain how immunotherapy helps the immune system recognize cancer cells and strengthen its response to destroy these cancer cells; and
-Recognize the limitations of current MRI techniques to assess response to immunotherapy.
The International Society for Magnetic Resonance in Medicine is accredited by the Accreditation Council for